BillionToOne's next report is less about whether demand is healthy and more about whether the plumbing behind that demand is working again. Last quarter, oncology volumes ran ahead of plan, yet total revenue barely moved sequentially, margins slipped and management held its full-year outlook steady after three straight raises. The company blamed true-up timing and roughly $10 million of claims held up while national payers implemented in-network codes. The third-quarter release, due after the close on November 4, is the first real chance to test that explanation.
The Street expects earnings of $0.16 per share on revenue of $117.2 million. That would be 60% EPS growth and about 40% revenue growth from a year ago, a strong rate though well below the 64% the company posted in the second quarter, partly because the comparisons get tougher. Sequentially, the forecast implies about 7% growth from $109.4 million, in line with the 8% underlying sequential growth management cited once true-up revenue was stripped out. In other words, consensus assumes the core business keeps compounding without much help from catch-up collections.
The guidance math is where the setup gets interesting. Management reaffirmed 2026 revenue of $450 million to $465 million, while the full-year consensus of about $449.8 million sits essentially at the low end. After first-half revenue of $217.8 million, hitting the third-quarter estimate would leave roughly $115 million needed in the fourth quarter to reach the bottom of the range, which is below the third-quarter forecast itself. Reaching the midpoint would require something closer to $122 million. Analysts appear to be pricing in some skepticism about collections, which lowers the bar. If the held claims are released and true-up revenue rebounds, BillionToOne has room to resume raising its outlook, and a return to that cadence would do more to repair the narrative than a modest EPS beat.
The operating details matter as much as the headline numbers. Average selling price fell about $20 sequentially to $551 on true-up timing even as the underlying figure rose on a record number of payer contracts, so a rebound in reported ASP would be strong evidence that the second quarter was noise. On the cost side, cost per test climbed to $161 as faster-growing but lower-margin oncology work took a larger share, and management warned gross margin could briefly fall below 70% if oncology outruns its model. That creates a tension: a further jump in the oncology run rate from roughly $55 million would confirm demand, but at some cost to margins. Operating margin, which dropped to 5% from 16%, should show whether the roughly 70 sales reps hired in the first half are beginning to pay for themselves or still diluting productivity. Updates on MolDx coverage for NorthStar Response and the tumor-naive MRD launch, both targeted by year-end, will shape how credible the company's 2027 acceleration story looks.
Sentiment has swung meaningfully, moving from a bearish reading before the last report to a moderately bullish one now, and the stock has gained 6% since that release while the S&P 500 slipped slightly. At $111.47, shares sit comfortably above the 200-day moving average near $96 and in the upper half of their post-earnings range of roughly $88 to $128, though well short of a breakout. The range has also narrowed considerably from the prior quarter's $77 to $150 swing, suggesting the market has calmed but not fully committed.
The central question is whether the second-quarter slowdown proves to be a timing hiccup. Recovered claims, firmer ASP and gross margin holding near 70% would validate management's account and reopen the door to higher guidance. Another flat quarter in reported revenue, or margins sliding further without a collections rebound, would suggest the pause in raises reflected something more durable than paperwork.